

Index

Page references in *italics* refer to figures.
Page references in **bold** refer to tables.

- Aberrant glands, 315–316
- Absolute effect measures, 150
- Accessory glands, 315–316
- Accessory parotid gland, 22, 315
 - occurrence, 40
 - sialadenitis, 47, 48
- Accessory salivary tissue, submandibular space, 44
- Acellular dermis, 301
- Achalasia, and sialadenosis, 144, 145, 146
- Acinar cells
 - age-related atrophy, 324
 - lymphohistiocyte-mediated destruction, 134
 - radiation injury, 307
 - sialadenosis, 146, 146
- Acinar ducts, dilated, 51
- Acini, 15, 16
- Acinic cell adenocarcinoma, lip, 251, 252
- Acinic cell carcinoma, 153, 190
 - gene expression profiling, 160
 - grading, 195
 - survival rates, 189–191
- Actin myofilaments, 15
- Acute bacterial parotitis, 67, 68, 75, 76
 - algorithm, 74
 - community acquired, 72–73
 - diagnosis, 73
 - diabetes mellitus and, 73
 - hospital acquired, 72–73, 74
 - parotid duct, 71, 73
 - and postoperative hydration, 71–72
 - Stenson's duct, 71
 - treatment, 73–74, 74
- Acute bacterial submandibular sialadenitis (ABSS), 82
- Adenitis, mycobacterial, 112, 113
- Adenocarcinomas, 153–156
 - not otherwise specified, 154
 - sublingual gland, 202
- Adenoid cystic carcinoma, 153
 - ADC values, 29
 - biomarkers, 160, 199
 - diagnostic imaging, 56, 56, 57
 - differentiating from polymorphous low-grade adenocarcinoma, 238, 243, 243
 - facial nerve palsy, 153, 201
 - gene expression profiling, 159–160
 - histopathology, 242
 - major salivary glands, 236
 - maxillectomy, 238, 241
 - minor salivary glands, 56, 56, 235, 236, 241–243
 - MRI, 193
 - palate, 236
 - perineural spread, 206, 238
 - prognosis, 238
 - radiation therapy, 238
 - sublingual gland, 56, 56, 210, 211
 - mandibulotomy, 210, 210, 211
 - submandibular gland, 56, 56, 199
 - histopathology, 201
 - survival rates, 189–191, 195, 206, 209, 238
 - tongue, 236
- Adenomyoepithelioma, 157
- Adenosquamous carcinoma, 158
- Adrenergic nerves, salivation and, 17
- AIDS. *See* HIV/AIDS
- Alcoholism, and sialadenosis, 144
- Aldosterone, 17
- Alpha particles, 32
- Amifostine, 307, 308, 309
- Amylase, 3, 15
- Amyotrophic lateral sclerosis, 322, 323
- Anaplastic small cell carcinoma, 157
- Androgen receptor, 258
- Aneurysms, 23, 46
- Angiography, 46
- Angiosarcoma, parotid gland, 269
- Angiotensin converting enzyme (ACE), 142
- Antiandrogen therapy, 258
- Antibiotics, prophylactic, 72
- Anticholinergics
 - for drooling, 322
 - for Frey's syndrome, 298
- Antihistamines, 73
- Antioxidants, saliva, 322
- Antisialogues
 - and acute bacterial parotitis, 73
 - to treat fistulae, 288

- AP-2 γ , 159
 Aplasia, 315
 Aplasia of the lacrimal and salivary glands (ALSG), 315
 Apoptosis-related genes, 160
 Apparent diffusion coefficient (ADC), 28–29
 Armed Forces Institute of Pathology (AFIP), 150
 Arteriovenous fistulae (AVFs), 23, 46–47
 Arthritis, in sarcoidosis, 141, 147
 Articular protuberance, 4
 Artifacts
 beam hardening, 23–24
 CT scanning, 23–24
 motion, 23, 24
 streak, 20
 susceptibility, 25–26, 29–30
 vascular pulsation, 29–30
 Atheromas, calcified, 116
 Attia double osteotomy, mandible, 226–227
 Auriculotemporal nerve, 5, 7–8, 10
 Australia, skin cancer in, 276
 Autoantibodies, 131
 Autoimmune diseases, associated with Sjogren's syndrome, 132, 147
- Babies, ranula, 315
 “Bag of worms,” 59–60
 Balloon dilatation, 306
 Barotrauma, 308
Bartonella henselae, 80, 81; *See also* Cat scratch disease
 Basal cell adenocarcinoma, 154
 Basal cell adenoma, 151–152
 Basaloid salivary carcinoma, 154
 B-cell lymphomas, in Sjogren's syndrome, 273–274
 Beam hardening artifact, 23–24
 Behavioral modification, 322
 Benign lymphoepithelial lesion
 histopathology, 140
 HIV-associated, 101–106
 lymphoma in, 133, 158–159
 malignant change, 134
 and Mikulicz's disease, 134, 135
 in Sjogren's syndrome, 133, 158
 Benign mesenchymal tumors, 263–268. *See also under individual tumor*
 Benign pleomorphic adenoma
 malignant transformation, 228
 recurrence, 228
 Benzhexol hydrochloride, 322
 Benztropine, 322
 Beta-blockers, 73
 Beta particles, 32
 Biglycan, 160
 Billroth, Theodore, 236
 Biofeedback, 322
 Biomarkers
 adenoid cystic carcinoma, 160, 199
 mucoepidermoid carcinoma, 160, 199
 pleomorphic adenoma, 199
 salivary, 322
 salivary duct cancer, 160
 tissue metalloproteinase inhibitors as, 160
 tumor, 150
 candidate genes, 160
 Bird's beak deformity, 145
 Blair incision, 191
 Blood, Hounsfield units, 22
 Blue dot tumor, 252
 B-lymphocytes, in benign lymphoepithelial lesion, 158
 Bone marrow, MRI T1 image, 25
 Bone windows, 23
 Botulinum toxins (A/B/F)
 to close fistulae, 288, 290, 293
 in duct repair, 302
 for Frey's syndrome, 298, 300, 309
 for sialoceles, 290, 293, 309
 to treat drooling, 322–323
- Brain
 edema
 MRI FLAIR image, 28
 MRI STIR image, 27
 glucose metabolism, 33
 lesions, MR spectroscopy, 29
 metal deposits, 27
 MRI T2 image, 25
 Brain tumors, markers, 30
 Branchial cleft cysts, 107, 317, 318, 319, 319, 320, 321
 histology, 320
 imaging, 52–53
 parotidectomy, 318, 318–319
 parotid gland, 320, 321
 physical examination, 200–201
 superficial parotidectomy, 321
 superficial to facial nerve, 319, 321
 type I, 52–53, 52, 107, 318
 type II, 52–53, 52, 107, 318
 Branchial cleft fistulae, 317
 Breast cancer, and salivary gland tumors, 171, 218–219
 Breath, shortness of, 140–141
 Brown adipose tissue (BAT), 33
 Buccal gland, 15
 Buccal mucosa
 lesion evaluation, 220
 mucocele, 93
 sialolithiasis, 126
 Buccal mucosa tumors
 acinic cell adenocarcinoma, 251, 252
 canalicular adenoma, 230–231
 epithelial-myoeithelial carcinoma, 253
 excisional vs. incisional biopsy, 220

- mucoepidermoid carcinoma, 232, 235
- pleomorphic adenoma, 228
- polymorphous low-grade adenocarcinoma, 154, 243
- Bulimia, and sialadenosis, 144
- Calculi. *See* Sialoliths
- Canalicular adenoma, 152, 229–230, 230, 231
 - histopathology, 229
- Cancer
 - biomarkers, candidate genes, 160
 - progression, gene expression profiling, 159–160, 167
- Candidiasis, 315
- Cannon ball lesions, 22
- Carcinoma ex lymphoepithelial lesion, 158
- Carcinoma ex mixed tumor, 156
- Carcinoma ex monomorphic adenoma, 154
- Carcinoma ex-pleomorphic adenoma, 156, 195, 228
- Carcinomas, undifferentiated, 157
- Carcinosarcoma
 - incidence, 228, 229
 - malignant change, 195
- Carotid artery, calcified atheromas, 116
- Carotid space, 38
- Casein kinase 1 gene, 159
- Cat scratch disease
 - multiple parotid masses, 51
 - submandibular gland, 80, 81
- CD4/CD8 ratio, sarcoidosis, 144
- CD8 lymphocytes, 87
- CD40, 273
- CD40L, 273
- Cell adhesion genes, 160
- Cell phone use, 171
- Cell proliferation genes, 160
- Central mucoepidermoid carcinoma, 152
- Cephalosporin, 73
- Cerebral palsy, 322
- Cerebrospinal fluid
 - MRI FLAIR image, 28
 - MRI image, 25
 - MRI STIR image, 27
- Cervical lymphadenopathy, 212
 - adjacent to parotid tail, 55
 - CT scan, 38
 - with sarcoidosis, 51
- Cervical lymph nodes
 - mycobacterial infection, 85
 - and parotid tumors, 172
 - polymorphous low-grade adenocarcinoma metastases, 249
- Cervical sympathetic ganglion, superior, 10
- Cervico-mandibular trunk, branchial cysts, 321
- Cetuximab, 258
- Cheek
 - carcinoma ex-pleomorphic adenoma, 228
 - squamous cell carcinoma, 277
- Cheek biting, 73
- Chemotherapy, minor salivary gland tumors, 258
- Chest
 - CT scan, 21, 22
 - pain, sarcoidosis, 140–141
- Chewing, difficulty in, 132
- Children
 - cystic lesions, 92
 - drooling, 322
 - hemangiomas, 263, 264
 - lymphangiomas, 45, 266
 - mucoepidermoid carcinoma, 233
 - parotid gland, 40
- Choline, 30
- Cholinergic agonists, 307
- Cholinergic nerves, salivation and, 17
- Chondroid lipomas, 267
- Chorda tympani, sectioning of, 323
- Chronic bacterial parotitis
 - etiology, 76
 - treatment, 78, 78–79, 80
- Chronic recurrent submandibular sialadenitis, 82–83, 83, 84, 85
- Chronic sclerosing sialadenitis, 48
- c-kit, 258
- Classification
 - aim of, 151, 167
 - classifier performance, 150
- Clear cell adenoma, 157
- Clear cell carcinoma, 154–155, 157
- Clear cell renal carcinoma, 284
- Clindamycin, 73
- Clinical stage, cancer. *See* Staging
- “Cluster of grapes,” 53
- Collagen sialadenitis, 88
- Complement fixation test, viral mumps, 87
- Computed tomography (CT)
 - advanced, 24
 - artifacts, 23–24
 - comparison to MRI, 20
 - contrast media, 20
 - lymphangioma, 45
 - parotid gland, 40
 - parotid tumors, 172–173, 174
 - technique, 20–24
- Computed tomography angiography (CTA), 23–24, 23
- Computed tomography perfusion, 24
- Congenital anomalies, first branchial cleft cyst, imaging, 52–53, 52
- Conjunctiva, Sjogren’s syndrome and, 132
- Connective tissue disorders
 - ADC values, 29
 - Sjogren’s syndrome and, 131, 147

- Contrast media
 CT, 20
 FDG, 33, 37, 40, 60
 gadolinium, 24, 27–28, 28, 40
 gallium, 32, 60
 iodine, 20
 iron oxide, 31
 Cornea, Sjogren's syndrome and, 132
 Coronal bone windows, 221
 Coxsackie A and B viruses, 87
 Costectomy, 182
 Cranial nerve 7. *See* Facial nerve
 Creatine, 30
 Crohn's disease, 144
 Cross-validation, 150
 CT. *See* Computed tomography
 CTA. *See* Computed tomography angiography
 Cylindroma, 153, 236
 Cystadenocarcinoma, 155
 Cystadenoma, 152
 Cystic fibrosis, 322
 Cystic hygroma, 45–46, 49, 266, 266
 Cystic lesions, classification and nomenclature, **92**
 Cystic pleomorphic adenoma, MR T1 and T2 images, 174
 Cyst of Blandin and Nuhn's gland, 99, 99
 Cysts, on MRI, 25
 Cytokeratin 14 gene, 160
 Cytokeratin 20 immunoreactivity, 280
 Cytokines, 131
 Cytoprotective agents, 307
 Cytotoxic T-cells, and radiation injury, 307
- D13S824E gene, 160
 Deep circumflex iliac artery flap, 208
 Dehydration, acute bacterial parotitis, 73
 Dental amalgam, 23
 Dental caries, 134, 315
 Dental chipping, 315
 Dental work, 70
 Deoxyglucose metabolism, 33; *See also* ¹⁸F-deoxyglucose (FDG)
 Dermatomyositis, 88
 Dermoid cysts, 46, 172
 Diabetes mellitus
 acute bacterial parotitis, 73
 sialadenitis, 70
 sialadenosis, 146
 Diazepam, to reduce BAT uptake, 33
 Diffuse infiltrative lymphocytosis syndrome (DILS), 88, 87–88
 Diffusion weighted images (DWI), 28–29, 63
 Digastric muscle
 anatomy, 9, 12, 37, 38, 40
 facial nerve and, 7, 176
 Digastric triangle, 11
 Digestive enzymes, salivary, 3
- Dingman mouth gag, 244
 “Dirty fat,” 47
 Distant metastases
 lymph node tumors, 280–283
 parotid gland tumors, 280, 283
 sublingual gland tumors, 210–211, 213
 DNA modification genes, 160
 Donor nerves, 298
 Doppler ultrasonography, 31, 32, 32, 46
 Drooling
 in children, 322
 treatment, 322–323
 Ductal papilloma, 152
 Duct atresia, 315
 Duct injuries
 botulinum toxins for, 302
 repair, 302, 304, 305
 transections, 301, 302, 303–304
 Duct ligation, for drooling, 323
 Duct of Bartholin, 44
 Duct repositioning, for drooling, 323
 Ducts of Rivinus, 44, 96
 DWI. *See* Diffusion weighted images (DWI)
 Dynamic contrast enhanced MRI, 30, 63
 Dynamic multi-slice contrast-enhanced CT, 24
 Dysphagia, 152
- Ear
 drainage from, 152
 numbness, 172
 Earring lesion, 38
 Ectodermal dysplasia, 315
Eikenella corrodens, 72
 Elderly, dehydration in, 67
 Electrolytes, 15, 17
 Embryonal rhabdomyosarcoma, 269
 Endothelin, 322
 Enteric cytopathic human orphan (ECHO) virus, 87
 Ephedrine, effect on BAT uptake, 33
 Epidermoid cysts, 46
 Epimyoeptithelial carcinoma, grading, 195
 Epimyoeptithelial islands, 101, 134, 140
 Epineural suture, 294, 296
 Epithelial growth factor receptor, 258
 Epithelial-myoeptithelial carcinoma, 157, 253, 253–257
 buccal mucosa, 253
 palate, 251
 parotid gland, 157, 253
 submandibular gland, 253
 Epithelial non-salivary tumors, 273
 Epsilon gene, 159
 Epstein-Barr virus, 87, 158
 Erythema nodosum, 140, 147
Escherichia coli, acute bacterial parotitis, 72
 Eskimo populations, tumors of, 158

- Estrogen receptors, 280
 Ethmoid sinus, tumor staging, **165–166**
 Ethylol, 307
 External acoustic meatus, 4, 5, 37, 38
 External carotid artery, 8–9, 9, 39
 Extracapsular excision, submandibular gland tumors, 203–204, 205, 206
 Extracorporeal sonographically-controlled lithotripsy, 120, 122
 Extrapulmonary oat cell carcinoma, 157–158
 Eyelids, metastatic squamous cell carcinoma, 279
 Eyes, dry, 131, 132
- Face lift incision, 176, 179–180, 181, 289
 Facial nerve, 5
 anastomotic arcades, 7
 branching patterns, 8, 9
 dissection
 submandibular gland excision, 202
 superficial parotidectomy, 7
 parotid gland, 5, 6, 9, 37, 39
 perineural spread along, 62
 predicting position, 172–173
 proximity to branchial cleft cysts, 319, 321
 and retromandibular vein, 9
 submandibular gland, 12–13
 surgical landmarks, 6, 7
 Facial nerve injury, 293–298
 epineural suture, 294
 fascicular suture, 294
 following stroke, 295
 gunshot wound, 294
 repair, 294–298, 309
 Facial nerve palsy, 51, 143, 147, 152, 153
 adenoid cystic carcinoma, 153, 201
 carcinoma ex-pleomorphic adenoma, 156
 lymphoepithelial carcinoma, 158
 mucoepidermoid carcinoma, 152
 neural tumors, 266
 parotid tumors, 172
 primary squamous cell carcinoma, 157
 sebaceous adenocarcinoma, 155
 Facial nerve schwannomas, 58
 Facial nerve trunk, branches, dissection of, 176, 178, 181, 182
 Facial skin, numbness, 172
 Facial trauma, sialadenitis associated with, 70
 Facial vein/artery
 parotid gland, 5, 6
 submandibular gland, 12, 13, 13, 14
 Fascicular suturing, 294
 Fast neutron therapy, 192
 Fat
 MRI image, 26
 MRI STIR image, 27
 Fat graft, to reduce hollowing, 178
- ¹⁸F-deoxyglucose (FDG), 33
 FDG PET
 neural tumors, 58–59
 normal parotid, 40
 FDG PET/CT, 37
 lymphoma staging and follow-up, 60
¹⁸F-Fluorodopamine PET/CT, 33
 FGF10, 315
 Fibrin adhesive, 296
 Fibrolipomas, 267
 Fibronectin, 72
 Fibronectin 1 gene, 160
 Fibrosarcoma, 159
 Fine needle aspiration biopsy
 image-guided, 31
 parotid tumors, 171, 173–174, 176
 salivary glands, false positive rates, 174–176
 submandibular gland tumors, 202
 First branchial arch, 317
 First branchial cleft cysts, 107, 317, 318, 319, 319, 320, 321
 histology, 320
 imaging, 52–53
 parotidectomy, 318, 318–319
 parotid gland, 320, 321
 physical examination, 200–201
 superficial parotidectomy, 321
 superficial to facial nerve, 319, 321
 type I, 52–53, 52, 107, 318
 type II, 52–53, 52, 107, 318
 Fistulae, 287, 288, 288, 289
 botulinum toxins for, 288, 290, 293
 from duct injuries, 301
 parotid gland, 287, 288, 309
 FLAIR. *See* Fluid attenuation inversion recovery (FLAIR)
 Flaps, to prevent hollowing, 301
 Flip angle, 27
 Flow voids, 46, 265
 Fluid attenuation inversion recovery (FLAIR), 28
 FNAB. *See* Fine needle aspiration biopsy
 Focus score, salivary gland biopsies, 138, 147
 Foley embolectomy catheter, 302
 Follicular lymphomas, 274
 Frey's syndrome, 176, 298–301, 309
 Frizzled-7 gene, 159
 Functional magnetic resonance imaging (fMRI), 29–30
Fusobacterium spp., 72, 88
- Gadolinium contrast-enhanced MRI, 24, 27–28, 28
 normal parotid, 40
⁶⁷Gallium, 32
⁶⁷Ga-citrate scintigraphy, staging and follow-up for lymphomas, 60
 Gamma rays, 32
 Gardner's syndrome, 115

- Gene expression profiling
 acinic cell carcinoma, 160
 adenoid cystic carcinoma, 159–160
 salivary gland tumors, 199
- Genomics, tumor profiling, 150
- Giant ranula, 49
- Gingiva, epithelial-myoepithelial carcinoma, 253–257
- Glass blowers, 308
- Glaucoma, 322
- Glucose metabolism, elevated, 33
- Glycerophosphocholine, 30
- Glycogen-rich adenoma (adenocarcinoma), 157
- Glycopyrrolate, 322
- Gout, 110
- Gradient recalled echo imaging (GRE), 26–27, 27
- Grading
 defined, 161
 malignant parotid tumors, 189–191, 195
 mucoepidermoid carcinoma, 153, 195, 232–233
 salivary gland tumors, 160
 submandibular gland tumors, 206, 209
- Granuloma, sarcoid, 144, 144
- GRE. *See* Gradient recalled echo imaging
- Greater auricular nerve, 5, 6, 10
 dissection of, 176, 177
- Greater palatine neurovascular bundle, 245, 247
- Growth factors, 307
- Gunshot wound
 duct injury, 305
 facial nerve injury, 294
 parotid sialoceles, 292, 293
- Gustatory sweating, 298, 300
- HAART. *See* Highly active antiretroviral therapy
- Haemophilus influenzae*, 72, 88
- Hard palate. *See also* Palate
 adenoid cystic carcinoma, 56, 57
 periosteal sacrificing, 223
 pleomorphic adenoma, 222, 223–224, 225, 225–228
 polymorphous low-grade adenocarcinoma, 154
- Hayes Martin maneuver, 204
- Hazard ratios, 150
- HCC-1 gene, 160
- Heerfordt's syndrome, 143, 147
- Hemangioendotheliomas, 263
- Hemangiomas, 263
 in children, 263, 264
 diagnostic imaging, 46–47, 46
 parotid gland, 263
 phleboliths in, 47, 112, 114, 116
 submandibular gland, 263, 265
- Hemangiopericytoma, 159
- Hemimandibulectomy, 212
- Hepatitis, mumps, 87
- Hepatitis C, risk of MALT lymphomas, 273
- her-2, 258
- Herpes labialis, 315
- Highly active antiretroviral therapy (HAART), 105, 106
- Hilar lymphadenopathy, 141, 147
- Hiroshima, 171, 220
- HIV/AIDS
 and acute bacterial parotitis, 74
 -associated benign lymphoepithelial lesion, 101–106
 -associated parotid cysts, 100–101, 102, 103, 104, 105, 105, 106
 -associated salivary gland disease, 87–88
 -lymphoepithelial lesions, diagnostic imaging, 49
 mumps associated with, 87
 risk of lymphomas, 273, 274
 sialadenitis associated with, 70
- Hodgkin's lymphoma, 273
- Hollowing, 178, 301
- Hounsfield unit (H), 21–22, 23
- Human immunodeficiency virus. *See* HIV/AIDS
- Hydration, post-operative, 71
- Hyoid bone, 12
- Hypoglossal nerve, sublingual gland tumors, 203, 210
- Imatinib, 258
- Immunoglobulin A, 3, 15, 17
- Immunoglobulin J chain gene, 160
- Incisional biopsy
 minor salivary gland tumors, 137–138, 220
 parotid gland, 138, 139, 140
 sialadenosis, 146, 146
- Incisions
 Blair, 191
 face lift, 176, 179–180, 181, 289
 lip split, 182, 184, 185, 210, 210, 211, 212
 modified Blair, 176, 177
 Weber-Ferguson, 136
- Incontinence medications, 73
- Indian filing pattern, 238
- Infants, ranula, 315
- Influenza virus, 87
- Insulin-like growth factor binding protein 5, 160
- Intensity-modulated radiation therapy, 307, 309
- Intercalated ducts, 15, 316
- Interferons, 131
- Interventional sialoendoscopy, 121–122, 121
- Intracorporeal endoscopically-guided lithotripsy, 120, 121
- Intraductal papilloma, 152
- Intraparotid masses, 172
- Intraparotid sentinel lymph node biopsy, 278
- Inuit population, tumors of, 158
- Inverted duct papilloma, 152
- Iodine, 20
¹²³I-MIBG SPECT, 33
- Iron oxide contrast media, 31
- Jacobson's nerve, sectioning of, 323
- Jugular vein, 5

- Kallikrein, 15
 Keratin genes, 158
 Keratoconjunctivitis sicca, 131, 132, 147, 323
 Ki-67, 199
 KIAA0074 gene, 160
 Kidney, metastases from, 280, 283
Klebsiella spp., 72, 88
 Kuttner tumor, 48
- Labial biopsy, sarcoidosis, 144
 Labial gland, 15
 Lacrimal gland
 enlargement, 134
 Sjogren's syndrome, 51
 Lacrimal probe
 salivary duct, sialadenitis, 70, 71
 Stenson's duct, 124
 Lacrimo-auriculo-dento-digital (LADD) syndrome, 315
 Lactoferrin, 3, 15
 Large B-cell intraparotid lymphoma, 60
 Large cell undifferentiated carcinoma, 158
 Laryngitis, 315
 Larynx, tumors of, 217
 Laser capture microdissection, 159
 Lasertripsy, 121
 Latissimus dorsi flap, 280
 Lazy S incision, 176, 177
 Leiomyosarcoma, 269
 Light sensitivity, 132
 Likelihood ratios, 150
 Linear discriminate analysis, 30
 Lingual arteries, 13
 Lingual gland
 anterior, 15
 posterior, 15
 Lingual nerve
 submandibular gland/duct, 13, 14
 sublingual gland tumors, 203, 210
 Linnaeus, Carolus, 149
 Lip
 cystic lesions, 92
 lesion evaluation, 220
 lower
 melanoma, 282–283
 mucocele, 93
 mucoepidermoid carcinoma, 152, 232
 sarcoidosis, 143
 sialolithiasis, 126
 tumors
 acinic cell adenocarcinoma, 251, 252
 excisional vs. incisional biopsy, 220
 mucoepidermoid carcinoma, 239–240
 pleomorphic adenoma, 228
 staging, **162–165**
 upper
 canalicular adenoma, 229
 carcinoma ex-pleomorphic adenoma, 228
 mucoepidermoid carcinoma, 232
 polymorphous low-grade adenocarcinoma, 154, 243, 249, 249–251
 Lipomas
 CT scan, 21
 diagnostic imaging, 21, 57, 58
 infiltrating, 267, 268
 parotid gland, 57, 58, 266–267
 parotid tail, 268
 submandibular gland, 267
 Lip split incision, mandibulotomy, 182, 184, 185, 210, 210, 211, 212
 Lithotripsy
 extracorporeal sonographically controlled, 120, 122
 intracorporeal endoscopically guided, 120, 121
 intraparotid stones, 124
 Lobular carcinoma, 238
 Lobules, salivary gland, 15
 Lofgren's syndrome, 141, 147
 Loop diuretics, 73
 Lorazepam, to reduce BAT uptake, 33
 Lower lip. *See* Lip, lower
 Low-grade adenocarcinoma, grading, 195
 Low-grade papillary adenocarcinoma of the palate, 155
 Lung, metastases from, 280, 283
 Lung window settings, 20–21, 22, 23
 Lymphadenopathy
 CT, 20
 ultrasonography, 31
 Lymphangioma, 263, 266, 266
 and aneurysms, 46
 children, 45, 266
 diagnostic imaging, 45–46
 differential diagnosis, 45–46
 sclerosing agents, 266
 submandibular gland, 45
 Lymph nodes
 calcified, 112, 113
 parotid, 9
 physical examination, 200
 tuberculous adenitis, 112, 113
 ultrasonography, 31, 31
 uptake of iron oxide, 31
 Lymph node tumors
 primary lymphomas, 273–276
 secondary
 distant metastases, 280–283
 regional metastases, 276–280
 Lymphocytes, grading, 138
 Lymphoepithelial carcinoma, 158
 Lymphoepithelial cysts
 HIV-associated, 100–101, 102, 103, 104, 105, 105, 106
 parotid gland, 49
 Lymphohistiocyte-mediated acinar destruction, 134

- Lymphoma, 273–276
 ADC values, 29
 in benign lymphoepithelial lesions, 133, 158–159
 clinical features, 274
 diagnostic imaging, 60–61, 60, 61
 etiology, 273–275
 multiple parotid masses, 51
 parotid tail, 60
 patient history, 274–275
 primary, 60
 secondary, 61
 in Sjogren's syndrome, 60, 133, 138, 147
 treatment, 276
- Lysozyme
 salivary, 3, 15
 tears, 132
- Magnetic resonance angiography (MRA), 46
- Magnetic resonance imaging (MRI), 24–25
 comparison to CT, 20
 cysts, 25
 diffusion weighted images (DWI), 28–29, 63
 dynamic contrast-enhanced, 30, 63
 fluid attenuation inversion recovery (FLAIR), 28
 fMRI, 29–30
 gadolinium-enhanced, 24, 27–28, 28
 normal parotid, 40
 gradient recalled echo imaging (GRE), 26–27, 27
 limitations, 63
 lymphangioma, 45
 magnetic resonance spectroscopy (MRS), 29–30, 63
 parotid tumors, 172–173, 174
 proton density images (PD), 26
 safety features, 24
 short tau inversion recovery (STIR), 27, 27
 spin-echo T1, 25, 26
 gadolinium-enhanced, 27–28, 28
 spin-echo T2, 25–26, 26
 gadolinium-enhanced, 27–28
 tissue characteristics, 26
- Magnetic resonance microscopy, 31, 63
- Magnetic resonance sialography, 30, 50, 63
- Magnetic resonance spectroscopy (MRS), 29–30, 63
- Magnetic resonance virtual endoscopy, 30–31
- Malignant basal cell adenoma, 154
- Malignant epithelial tumors, most common, 153
- Malignant fibrous histiocytoma, 159, 269
- Malignant hemangioendothelioma, 269
- Malignant melanoma, regional metastases, 276
- Malignant mesenchymal salivary gland tumors, 159
- Malignant mixed tumor, 156, 195, 228
- Malignant papillary cystadenoma, 155
- Malignant schwannomas, 159, 269
- Malignant secondary neoplasms, 159
- Malignant syringoma, 276
- Malnutrition, acute bacterial parotitis, 73
- MALT lymphoma, 134, 158–159, 273, 275
 diagnostic imaging, 60–61, 60, 61
 survival rates, 276
- Mandible, 4, 38
 Attia double osteotomy, 226–227
 osteoma, 112, 115
- Mandibular condyle, 4
- Mandibular fossa, 4
- Mandibulostylohyoid ligament, 6, 6
- Mandibulotomy
 adenoid cystic carcinoma, sublingual gland, 210, 210, 211
 parotid tumors, 182, 182, 184, 185
- Marsupialization, ranula, 96
- Masseter muscle, 5, 6
 intramuscular hemangiomas, 263, 264
- Masticator space, 38
- Mastoid process, 4
- Maxillary artery, 8
- Maxillary sinus, adenoid cystic carcinoma, 56, 57
- Maxillectomy
 adenoid cystic carcinoma, 238, 241
 partial, epithelial-myoepithelial carcinoma, 254–257
 polymorphous low-grade adenocarcinoma, 247–248
 radical, 238
 transoral partial, mucoepidermoid carcinoma, 237
- Measles-mumps-rubella (MMR) vaccine, 87
- Mechanoreceptors, 17
- Melanoma
 desmoplastic subtype, 62
 histopathology, 283
 lower lip, 282–283
 metastases, 61–62, 159
 nodular, 281
- Merkel cell tumors, metastases, 61, 276
- Mesenchymal neoplasms, 159
- Metal deposits, brain, 27
- Metallic implants, 23–24
- Metalloproteinases, 131
- Metastases, 159
 diagnostic imaging, 61–62
 distant. *See* Distant metastases
 regional. *See* Regional metastases
 skip, 204
- Metastasizing mixed tumor, 156, 228, 229
- Metastasizing pleomorphic adenoma, 228, 229
- Methicillin resistant *S. aureus* (MRSA), acute bacterial parotitis, 72, 75, 88
- ³H-1-Methionine, 33
- Microarray analysis, salivary gland tumor, 159–160
- Microliths, 316
- Middle ear, aberrant glands, 316
- Mikulicz's disease, 134, 135
- Minor salivary glands, 15
 anatomy, for diagnostic imaging, 44
 incisional biopsy, 137–138

- mucous escape reaction, 92
- necrotizing sialometaplasia, 323–324, 324
- saliva production, 3
- sarcoidosis, biopsy, 144
- sialolithiasis, 110, 126, 127, 128
- Sjogren's syndrome, 134, 136, 137
- Minor salivary gland tumors
 - acinic cell adenocarcinoma, 251, 252
 - adenoid cystic carcinoma, 56, 56, 235, 236, 241–243
 - anatomic barriers for surgery, 220–221, **222**
 - benign vs. malignant, 218, **219, 221**
 - canalicular adenoma, 229–230, 230, 231
 - carcinoma ex-pleomorphic adenoma, 228
 - cervical metastases, 258
 - chemotherapy, 258
 - clear cell carcinoma, 154–155
 - differential diagnosis, 219–220
 - epithelial-myoepithelial carcinoma, 157, 251, 253, 253–257
 - etiology, 218–219
 - imaging, 220
 - incidence, 217–218, **219, 221**
 - incisional biopsy, 137–138, 220
 - mucoepidermoid carcinoma, 55–56, 232–235
 - neck dissection, 257–258
 - patient history, 220
 - pleomorphic adenoma, 222–228
 - polymorphous low-grade adenocarcinoma, 154, 238, 243, 244–246, 247, 247–248, 249, 250–251
 - primary lymphomas, 273
 - radiation therapy, 258
 - sites of, **221**
 - staging, **162–165**
- Mixed tumor. *See* Pleomorphic adenoma
- Modified Blair incision, 176, 177
- Monomorphic adenoma, 151–152, 229
- Monomorphic clear cell tumor, 157
- Motion artifacts, 23, 24
- Mouth
 - dry, 131
 - ranula, 92, 93, 93, 94
- MRI. *See* Magnetic resonance imaging
- MRS. *See* Magnetic resonance spectroscopy
- Mucocele, 91, 93, 107, 290
- Mucoepidermoid carcinoma, 152–153, 232–235
 - ADC values, 29
 - biomarkers, 160, 199
 - buccal mucosa, 232, 235
 - children, 233
 - clear cell variant, 284
 - diagnostic imaging, 55–56, 55, 56
 - epidermoid cell, 233
 - fixed to mandible, 212
 - gene expression profiling, 160
 - grading, 153, 195, 232–233
 - histopathology, 208, 233, 234, 239, 240
 - intermediate cell, 233
 - lip, 152, 232, 239–240
 - minor salivary glands, 55–56, 232–235
 - mucous secreting cell, 233
 - neck dissection, 235
 - palate, 232, 233, 233–235, 235, 236–238, 238
 - parotid gland, 55–56, 55, 56, 152, 233
 - with perineural invasion, 240
 - radiation therapy, 235
 - sublingual gland, 211
 - submandibular gland, 199
 - survival rates, 189–191
 - treatment, 233
- Mucopapillary cysts, 99–100
- Mucosa-associated lymphoid tissue (MALT) lymphoma.
 - See* MALT lymphoma
- Mucosal melanoma, parotid metastases, 282–283
- Mucous escape reaction, 91–92
 - clinical features, 92–99
 - diagnostic imaging, 49
 - treatment, 96–99
- Mucous retention cysts, 91, 99–100, 107
- Mucous retention reaction, 91
 - cyst of Blandin and Nuhn's gland, 99, 99
- Mucus-producing adenopapillary carcinoma, 155
- Multiple-row detector CT (MDCT), 20
- Multiple sclerosis, MRI DWI, 28
- Multiplicative effect measures, 150
- Mumps, 47, 71
 - complications, 87
 - viral, 87
- Mural nodules, 49
- Musicians, barotrauma, 308
- Mycobacterial disease
 - adenitis, 112, 113
 - nontuberculous, 85, 86
 - tuberculous, 48, 51, 85
- Mycobacterium avium-intracellulare*, 85, 86
- Mycobacterium Kansasii*, 85
- Mycobacterium scrofulaceum*, 85
- Mycobacterium tuberculosis*, 85
- Mylohyoid boutonniere, 44
- Mylohyoid line, 12
- Mylohyoid muscle, discontinuities, 94–95
- Myocarditis, mumps, 87
- Myoepithelial carcinoma, 158
- Myoepithelial cells, 15, 134
- Myoepithelial islands, benign lymphoepithelial lesion, 158
- Myoepithelioma, 152
- Myxoid liposarcoma, 269

- Nagasaki, 171, 218
- Nasal cartilage, sarcoidosis, 142
- Nasal cavity tumors, **165, 217**

- Nasopharynx
 metastases from, 280
 tumors of, 217
- National Cancer Institute (NCI), 150
- Neck
 aberrant glands, 316
 CT scan, 20, 21
 soft tissue window, 22
- Neck dissection, 206
 metastatic squamous cell carcinoma, 278
 minor salivary gland tumors, 257–258
 mucoepidermoid carcinoma, 235
 radical, nodular melanoma, 281
 supraomohyoid, 209, 210, 211
 type 1 modified radical, 206, 210, 212
- Necrotizing sialometaplasia, minor salivary glands, 323–324, 324
- Nerve expander, 298
- Nerve grafts, 298
- Nerves, donor, 298
- Neural network analysis, 30
- Neural tumors, 266, 267
- Neurilemmomas, 266
- Neurofibroma, 58–59, 266
- Neurofibromatosis, 266
- Neurogenic tumors, diagnostic imaging, 58–60
- Nicotine, effect on BAT uptake, 33
- Non-Hodgkin's lymphoma, 273, 274
 parotid gland, 158, 274
 sublingual gland, 273
- Nutritional disturbances, and sialadenosis, 144, 146
- Obturator, 255
 definitive, 246, 256
 immediate, 245, 248
- Omega face lift incision, 176, 181
 parotidectomy, 179–180
 shotgun wound, 289
- Oncocytes, 54–55
- Oncocytoma, 55, 152, 155, 324
- Oncocytosis, 324
- Oral cancer, 217
 salivary biomarkers, 322
 tumor staging, **162–165**
- Oral motor therapy, 322
- Oral mucosa, 44
- Orofacial regulation therapy, 322
- Oropharynx, metastases from, 280
- Orthodontic brackets, 70
- Osteoma, mandible, 112, 115
- Otic ganglion, 10
- p53, 197
- Palatal gland, 15
- Palatal stent, 222, 235
- Palate. *See also* Hard palate; Soft palate
 mucoceles, 93
 necrotizing sialometaplasia, 323–324, 324
 tumors, 217
 adenoid cystic carcinoma, 236
 bony involvement, 220–221, 225
 carcinoma ex-pleomorphic adenoma, 228
 cupping out, 220, 225
 epithelial-myoepithelial carcinoma, 251
 incisional biopsy, 220
 lesion evaluation, 220
 mucoepidermoid carcinoma, 232, 233, 233–235, 235, 236–238, 238
 pleomorphic adenoma, 222, 223–224, 225, 225–228
 polymorphous low-grade adenocarcinoma, 154, 243
- “Panda sign,” 51
- Panoramic radiographs, sialolithiasis, 69
- Papillary adenocarcinoma, 155
- Papillary cystadenoma lymphomatosum. *See* Warthin's tumor
- Papillotomy, 118
- Parainfluenza virus, 87
- Paramyxovirus
 acute sialadenitis, 47
 mumps, 87
- Paranasal sinuses, tumor staging, **165**
- Parapharyngeal space
 giant ranula, 49
 growth of soft palate tumors into, 222, 225
 pleomorphic adenoma, 182, 183
- Parasympathetic innervation
 salivary glands, 11
 submandibular gland, 13–14
- Parasympathetic secretomotor nerve supply, parotid, 10
- Parkinson's disease, reduced saliva production, 322
- Parotid cysts, 172
 HIV-associated, 100–101, 102, 103, 104, 105, 105, 106
- Parotid duct, 5, 5, 6, 10, 22, 40
 acute bacterial parotitis, 71, 73
 injury to, 70, 73
 lacrimal probe, 124
 ligation, for drooling, 323
 obstruction, 305
 repair, 302, 305
 sialoendoscopy, 77
 sialoliths, 11, 123
 strictures, 124
 surface markings, 10
- Parotidectomy, 124
 benign lymphoepithelial lesions, 105
 for chronic bacterial parotitis, 78–79
 face lift approach, 174, 177–178, 179
 first branchial cleft anomalies, 318, 318–319
 for Frey's syndrome, 300–301
 hollowing, 301
 mycobacterial disease, 86

- nodular melanoma, 281
- pleomorphic adenoma, 175–176
- primary desmoid melanoma, 272
- Parotid emphysema, 308
- Parotid gland
 - acini, 15
 - acute bacterial parotitis. *See* Acute bacterial parotitis
 - anatomy, 4–6, 4, 5, 37–40
 - associated structures, 5, 12
 - auriculotemporal nerve, 7–8
 - blunt trauma, algorithm, 310
 - bony features related to, 4, 4
 - borders of, 5–6
 - branchial cleft cysts, 320, 321
 - capsule, 4–5
 - chronic inflammatory changes, 48
 - CT
 - adjacent structures, 38
 - density, 23, 38
 - normal scan, 36, 40
 - deep surface, 6
 - embryology, 3–4
 - external carotid artery, 8–9, 9
 - facial nerve, 6–7, 37, 39
 - fascia, 6
 - fistulae, 287, 288, 309
 - gadolinium contrast, 40
 - HIV infection and, 101
 - hypoplasia, 315
 - imaging, 37–40
 - incisional biopsy, 138, 139, 140
 - infectious process, 70
 - lymph nodes, 9
 - metastases, 61–62
 - squamous cell carcinoma metastases, 276, 277, 278
 - lymphoepithelial cysts, 49
 - metastases to, 159
 - milking, 71, 73
 - MRI
 - STIR image, 27, 38
 - T1 image, 38
 - mucous retention cysts, 99–100, 100, 107
 - mumps, 87
 - mycobacterial disease, 85, 86
 - nerve supply to, 10
 - pediatric, 40
 - penetrating injuries, algorithm, 309
 - PET, 36
 - radioiodine damage, 308
 - retromandibular vein, 8, 9
 - saliva composition, **110**
 - saliva production, 3
 - sarcoidosis, 51, 142, 143
 - sialadenitis, 67, 70, 88
 - sialadenosis, 144–146, 147
 - biopsy, 146, 146
 - sialocele, 290–293, 290, 309
 - gunshot wound, 292, 293
 - sialolithiasis, 110–111, 122, 123, 124
 - sialolithotomy, 124, 125, 126
 - sialoliths, CT scan, 50, 50, 125
 - Sjogren's syndrome, 132, 133, 135
 - standardized uptake value (SUV), 35
 - superficial surface, 6
 - traumatic fistulae, 287, 288
 - ultrasound of, 31, 32, 40
 - vascular lesions, 46
- Parotid gland tumors
 - acinic cell carcinoma, 153
 - angiosarcoma, 269
 - deep lobe, 182, 183, 187, 188
 - diagnosis
 - differential, 172
 - fine needle aspiration biopsy, 173–174, 176
 - history, 171–172
 - imaging, 172
 - physical examination, 172
 - distant metastases, 280, 283
 - epidemiology, 171
 - epithelial-myoepithelial carcinoma, 157, 253
 - etiology, 171
 - incidence, 44
 - large cell undifferentiated carcinoma, 158
 - lipomas, 57, 58, 266–267
 - lymphoepithelial carcinoma, 158
 - malignant
 - grading and prognosis, 189–191, 195
 - survival rates, 189
 - treatment groups, 191–195
 - mandibulotomy, 182, 182, 184, 185
 - metastatic melanoma, 61, 62
 - metastatic squamous cell carcinoma, 62
 - MRI, 172–173, 174
 - mucoepidermoid carcinoma, 55–56, 55, 56, 152, 233
 - neoplastic process, 70
 - neurofibromas, 266
 - neurogenic, 58–60
 - non-Hodgkin's lymphoma, 158, 274
 - oncocytoma, 55, 155
 - pleomorphic adenoma, 53, 177–178, 186–189
 - biopsy/parotidectomy, 175–176
 - polymorphous low-grade adenocarcinoma, 243
 - primary desmoid melanoma, 272
 - primary lymphomas, 273
 - primary squamous cell carcinoma, 156–157
 - survival rates, 195
 - regional metastases, 276
 - sebaceous adenocarcinoma, 155
 - superficial lobe, 177, 187
 - treatment
 - extracapsular dissection, 187

- Parotid gland tumors (*Continued*)
 facial nerve sacrifice/preservation, 192–195
 mandibulotomy, 182, 182, 184, 185
 neck dissection, 192–195
 radiation therapy, 192
 retrograde parotidectomy, 176
 superficial parotidectomy, 176, 177–179, 182
 total parotidectomy, 176, 179–180, 181, 182
 vascular tumors, 263, 264
 Warthin's tumor, 151, 189
- Parotid saliva
 fibronectin in, 72
 radiation sensitivity, 307
- Parotid space, 38
- Parotid tail, 38
 adjacent cervical lymphadenopathy, 55
- Parotid tail tumors, 172, 172, 173
 lipomas, 268
 lymphoma, 60
 pleomorphic adenoma, 187, 187, 188, 189
 Warthin's, 172, 189
- Parotitis, 143, 147
 postoperative, 72
 viral, 47
- Partial parotidectomy, parotid sialocele from gunshot
 wound, 292
- PCNA, 199
- PD. *See* Proton density images
- Penetrating injuries
 duct stenosis, 305, 306
 duct transection, 301, 302, 303–304
 fistulae, 287, 288, 288, 289
 Frey's syndrome, 298, 300, 301
 hollowing, 301
 nerve injury, 293–298
 parotid gland, algorithm, 309
 sialocele, 290–293
- Penicillin, 73
- Perineural spread, 62
 adenoid cystic carcinoma, 204, 238
 gene expression profiling, 159
 mucoepidermoid carcinoma, 240
- Pes anserinus, 7
- PET. *See* Positron emission tomography
- Petrosal nerve, 10
- Pharyngeal constrictor muscle, 6
- Pharyngeal space, 38
- Pharyngitis, 315
- Pharynx, aberrant glands, 316
- Phleboliths, 46, 47, 112, 114, 116
- Phosphatidylcholine, 30
- Phosphocholine, 30
- Phosphocreatine, 30
- Pilocarpine, 308, 309
- Plasma cells, grading, 138
- Platelet rich plasma (PRP), 296
- Platysma muscle, 5
- Pleomorphic adenoma, 151, 167
 acanthomatous variant, 223
 ADC maps, 29
 biomarkers, 199
 buccal mucosa, 228
 choline to creatine ratio, 30
 cut specimen, 223
 diagnostic imaging, 53–54, 53, 54
 dissection, 204
 enhancement curve, 30
 extracapsular dissection vs. parotidectomy, 186–187
 histopathology, 224
 incidence, 222
 lip, 228
 malignant, 195, 228
 minor salivary glands, 222–228
 MRI T1 and T2 images, 174
 palate, 222, 223–224, 225, 225–228
 parapharyngeal space, 182, 183
 parotid gland, 53, 177–178, 186–189
 biopsy/parotidectomy, 175–176
 postoperative tissue bed, 224
 pseudocapsule, 186, 222, 224
 recurrence rate, 186–187, 188, 189
 sites of, 222
 stroma rich, 186
 submandibular gland, 199, 202, 207–208
 histopathology, 202
 tongue, 228
- Plexiform neurofibroma, 59, 266, 267
- Plunging ranula, 49, 95, 95
 physical examination, 200
 sublingual gland excision, 96–97, 98
- Pneumoballistic energy, 121
- Pneumoparotid, 308
- Polycystic disease, 316, 316, 317
- Polyglycolic acid tube, 298
- Polymorphous low-grade adenocarcinoma, 154
 buccal mucosa, 154, 243
 differentiating from adenoid cystic carcinoma, 238, 243, 243
 histopathology, 245, 246
 maxillectomy, 247–248
 metastases, 249
 minor salivary glands, 154, 238, 243, 244–246, 247, 247–248, 249, 250–251
 nonpapillary form, 243
 palate, 154, 243
 papillary form, 243
 parotid, 243
 perineural spread, 243
 radiation therapy, 249
 survival rate, 249
 treatment, 243, 249, 249–251
 upper lip, 243, 249, 249–251

- Polymyositis, 88
- Positron, 32
- Positron emission tomography (PET)
- acquisition times, 33
 - annihilation event, 32
 - artifacts, 33
 - radionuclides, 33
 - standardized uptake value (SUV), 34–36, **37**
- Positron emission tomography/computed tomography (PET/CT), 37
- benefits, 63
 - false negatives, 37
 - limitations, 63
 - radionuclides, 33
- Prevotella* spp., 72, 88
- Primary desmoid melanoma, parotid gland, 272
- Primary lymphomas, 273
- Primary mucinous adenocarcinoma, 156
- Primary salivary gland tumors, 159
- Primary squamous cell carcinoma, 156–157, 195
- Propranolol, effect on FDG uptake, 33
- Prostate carcinoma tumor antigen, 160
- Protein deficiency, and sialadenosis, 144
- Proteins, 17
- Proteomics, tumor profiling, 150
- Proteus* spp., 72, 88
- Proton density images (PD), 26
- Proton distribution, and MRI, 24
- Pseudoaneurysms, 46
- Pseudomonas* spp., acute bacterial parotitis, 72, 88
- Pseudopodia, and recurrence rate, 186
- Pterygoid muscles, 6
- Radiation exposure
- chronic sialadenitis due to, 48
 - risk of mucoepidermoid carcinoma, 152
 - risk of primary squamous cell carcinoma, 157
 - risk of salivary gland tumors, 218
- Radiation injury
- preventing, 307–308
 - xerostomia, 306–307
- Radiation therapy
- adenoid cystic carcinoma, 238
 - for drooling, 323
 - metastatic squamous cell carcinoma, 278
 - minor salivary gland tumors, 258
 - mucoepidermoid carcinoma, 235
 - polymorphous low-grade adenocarcinoma, 249
 - and skin cancer risk, 218
 - sublingual gland tumors, 210
 - submandibular gland tumors, 206, 209
 - wide field adjuvant, 195
- Radiation Therapy Oncology Group (RTOG), 308
- Radioactive iodine, 308
- Radiofrequency pulse, MRI, 24
- Radionuclide imaging (RNI), 32, 33
- Ranula, 91, 93–99, 107, 290
- appearance, 93
 - babies, 315
 - giant, 49
 - marsupialization, 96
 - mouth, 92, 93, 93, 94
 - oral and cervical mucous escape reactions, 93–94
 - plunging. *See* Plunging ranula
 - recurrence rate, 96
 - and scar tissue formation, 94, 95
 - simple, 49
 - treatment, 95–99
- Reactive nitrogen species, saliva, 322
- Reactive oncocytoid cysts, 99–100
- Recurrent juvenile parotitis, 80
- Regional metastases, 276–280
- Renal cell carcinoma, 284
- Reserpine, effect on FDG uptake, 33
- Respiratory symptoms, sarcoidosis, 140–141, 141, 147
- Reticuloendothelial system, uptake of iron oxide, 31
- Retrograde infection
- acute bacterial parotitis, 73
 - and sialadenitis, 72
- Retrograde parotidectomy, 176
- Retromandibular vein, 8, 9, 22
- in facial nerve positioning, 173
- Rhabdomyosarcoma, 159
- Rheumatoid arthritis, 131
- Rhinorrhea, 288
- Ribonucleoprotein particles, 131
- RNI. *See* Radionuclide imaging
- Rose Bengal stain, 132
- Rose Hanger skin test, 80
- Saliva
- antioxidant profile, 322
 - calcium in, 322
 - composition, 3, **110**
 - in cystic fibrosis, 322
 - deficiencies, 3
 - as diagnostic fluid, 322
 - endothelin, 322
 - FDG in, 35
 - function, 3
 - production
 - in Parkinson's disease, 322
 - rate, 3
 - proteins in, 17
 - reactive nitrogen species, 322
 - secretory pressure, 15
 - viscosity, 110
- Salivary carcinosarcoma, 156
- Salivary duct
- cannulation of, 70
 - severance of, 91–92, 107
 - traumatic injuries, 301, 302, 303–304

- Salivary duct carcinoma, 155–156, 157
 biomarkers, 160
 gene expression profiling, 160
 primary, enhancement curve, 30
- Salivary glands
 age changes, 324
 apparent diffusion coefficient (ADC) values, 28–29
 biopsy
 complications of, 138
 Sjogren's syndrome, 137–138, 138, 139
 CT density, 23
 fine needle aspiration biopsy, false positive rates, 174–176
 histology, 15, 16
 imaging choices, 62–63
 incisional biopsy, sialadenosis, 146
 infections
 classification of, **69**
 risk factors for, **69**
 lymphohistiocyte-mediated acinar destruction, 134
 minor. *See* Minor salivary glands
 parasympathetic innervation, 11
 physical examination, 70
 standardized uptake value (SUV), 34–36, **37**
 systemic disease, 131, 147; *See also individual disease*
 vascular pathology, 23
- Salivary gland tumors
 cellular classification, 150, **151**, 167
 gene expression profiling, 199
 grading, **160**
 histological variability, 150
 microscopic diagnosis, 218
 occurrence, 171
 staging, **160–166**
 standardized uptake value (SUV) and, 37
- Salivary scintigraphy, 37
- Salivary sludge, 70–71, 71
- Salivary stasis, 110
- Salivation, control of, 17
- Salivatory nucleus, inferior, 10
- “Salt and pepper” appearance, 51
- Sarcoidosis
 clinical features, 140–141, **140**, 141, 147
 diagnostic imaging, 48, 51
 differentiating from Sjogren's syndrome, 142
 histopathology, 144, 144
 labial biopsy, 144
 lip, 143
 minor salivary gland biopsy, 144
 parotid involvement, 51, 142, 143
 submandibular gland, 143
 type II, 141
- Scanning electron microscopy (SEM), sialoliths, 109
- Schirmer test, 132
- Schwann cells, 17
- Schwannomas
 diagnostic imaging, 58–60, 58, 59
 malignant, 159, 269
- Scientific classification, 149
- Scleroderma, 88
- Sclerosing agents, lymphangiomas, 266
- Scopolamine, 323
- Scrofula, 112, 113
- Sebaceous adenocarcinoma, 155
- Sebaceous adenoma, 152
- Sebaceous cysts, 172
- Sebaceous lymphadenocarcinoma, 155
- Sebaceous lymphadenoma, 152
- Second branchial arch anomalies, 53, 317
- Secretory droplets, 15
- Sensory innervation, submandibular gland, 14
- Serous cells, radiation sensitivity, 306–307
- Serous demilunes, 15
- Shock wave lithotomy, 117, 120, 121
- Shock wave lithotripsy, parotid sialoliths, 124
- Short tau inversion recovery (STIR), 27, 27
- Shotgun wound
 Frey's syndrome, 298
 omega face lift incision, 289
- Sialadenectomy, 83–85
- Sialadenitis
 accessory parotid gland, 47, 48
 acute, diagnostic imaging, 47
 chronic
 diagnostic imaging, 48–49
 recurrent, 82–83, 83, 84, 85
 sclerosing, 48
 diabetes mellitus and, 70
 Gram-negative, 72
 Gram-positive, 72
 histopathology, 79, 85
 occlusal radiograph, 71
 panoramic radiograph, 71, 74
 parotid gland, 67, 70, 88
 patient history, 67, 70
 physical examination, 70
 from radioiodine, 308
 risk factors, 70, 72
 submandibular gland, 67, 69, 88
 chronic recurrent, 82–83, 83, 84, 85
- Sialadenoma papilliferum, 152
- Sialadenosis
 classification, **145**
 clinical features, 146
 diagnosis, 146
 diabetes mellitus and, 144, 146
 imaging, 50
 parotid gland, 144–146, 147
- Sialoblastoma, 152
- Sialocele, 290–293

- aspiration, 290
- botulinum toxins for, 290, 293, 309
- due to duct injury, 301, 303
- parotid, 290–293, 290, 309
- Sialodochoplasty, 116, 118, 306
 - with duct repositioning, 302
 - Wharton's duct tumor, 208
- Sialoendoscopy, 76, 77, 78, 80
 - interventional, 121–122, 121
 - strictures, 305–306
- Sialogram, 303
- Sialography, 20
- Sialolipoma, 267
- Sialolithiasis
 - buccal mucosa, 126
 - clinical features, 110–111
 - diagnostic imaging, 48, 50, 50, 51
 - differential diagnosis, 112, 113–115, 116
 - lip, 126
 - minor salivary glands, 110, 126, 127, 128
 - panoramic radiographs, 69
 - parotid gland, 110–111
 - algorithm, 122
 - extraglandular duct, 122, 123
 - intraglandular duct, 122, 124
 - lithotripsy, 124
 - parotidectomy, 124
 - shock wave lithotripsy, 124
 - sialolithotomy, 124, 125, 126
 - transoral sialolithotomy, 123, 124
 - treatment, 122–126
 - pathophysiology, 109–110
 - sublingual gland, 48, 110–111
 - submandibular gland, 50, 50, 51
 - algorithm, 117
 - gland excision, 117, 119, 120
 - interventional sialoendoscopy, 121–122, 121
 - shockwave lithotomy, 117, 120, 121
 - sialodochoplasty, 116, 118
 - transoral sialolithotomy, 116, 118
 - treatment, 116–122
- Sialolithotomy
 - parotid gland, 124, 125, 126
 - submandibular gland, 116, 118
- Sialoliths, 47
 - CT scan, 21
 - formation of, 109
 - parotid gland, 50, 50, 125
 - submandibular gland, 50, 51, 69, 111, 112
- Sialorrhea, 322–323
- Sialosis. *See* Sialadenosis
- Sjogren's syndrome, 47
 - B-cell lymphomas, 273–274
 - benign lymphoepithelial lesions in, 101, 131, 158
 - chronic inflammatory changes, 48
 - clinical features, 132–134
 - diagnostic imaging, 51
 - differentiating from DILS, 88
 - differentiating from sarcoidosis, 144
 - extraglandular manifestations, 131, 132
 - histopathology, 140, 140
 - keratoconjunctivitis sicca, 131, 132, 147
 - lymphoma in, 60, 133, 138, 147
 - minor salivary glands, 134, 136, 137
 - parotid gland lesions, 132, 133, 135
 - primary, 51, 131–132
 - salivary gland biopsy, 137–138, 138, 139
 - secondary, 51, 132
 - submandibular gland, 132, 134, 136, 137
- SKAP 55 protein, 160
- Skin cancer, regional metastases, 276
- Skip metastases, 204
- Skull
 - CT scan, 21
 - MRI STIR image, 27
 - MRI T1 image, 25
- Slit lamp examination, 132
- Small cell lung cancer, 280, 283
- Small cell undifferentiated carcinoma, 157–158
- SMAS. *See* Superficial musculo-aponeurotic system
- Smoking, and Warthin's tumor, 171, 189
- Soft palate. *See also* Palate
 - pleomorphic adenoma, 222, 223–224, 225, 225–228
 - polymorphous low-grade adenocarcinoma, 154, 243, 244–246
- Soft tissue windows, 22, 23
- Soluble (S) antibodies, 87
- SON DNA-binding protein, 160
- Sour ball candies
 - for acute bacterial parotitis, 73
 - for acute bacterial submandibular sialadenitis (ABSS), 82
- Sour gum test, 120
- SOX4, 159
- SPECT imaging, 32, 33, 63
- Spheroliths, 316
- Spindle cell/pleomorphic lipomas, 267
- Squamous cell carcinoma
 - metastases, 61–62, 159
 - metastatic cutaneous, 276, 277, 278, 279, 280
 - primary. *See* Primary squamous cell carcinoma
 - regional metastases, 276
 - standardized uptake value (SUV) and, 37
- SS-A/Ro, 131
- SS-B/La, 131
- Staging
 - defined, 161
 - malignant parotid tumors, 195
 - minor salivary gland tumors, 162–165
 - nasal cavity tumors, 165
 - parameters, 161, 167

Staging (*Continued*)salivary gland tumors, **161–166**

submandibular gland tumors, 206, 209

Standardized uptake value (SUV), salivary glands, 34–36, **37***Staphylococcus aureus*, acute bacterial parotitis, 72, 88*Staphylococcus* spp.

acute sialadenitis, 47

chronic bacterial parotitis, 76

Stenson's (Stensen's) duct, 5, 5, 6, 10, 22, 40

acute bacterial parotitis, 71, 73

injury to, 70, 73

lacrimal probe, 124

ligation, for drooling, 323

obstruction, 305

repair, 302, 305

sialoendoscopy, 77

sialolith in, 111, 123

strictures, 124

surface markings, 10

Stenson's papilla, 122, 123, 302

Stents, in duct repair, 302

Sternocleidomastoid muscle, 5, 38

dissection of, 176, 177

Stevens-Johnson syndrome, 323

STIR. *See* Short tau inversion recovery (STIR)

Streak artifacts, 20

Streptococcus spp.

acute bacterial parotitis, 72, 88

acute sialadenitis, 47

chronic bacterial parotitis, 76

Striated ducts, 15, 17

Stroke

facial nerve injury, 295

MRI DWI, 28

Styloid process, 4, 6

Stylomandibular ligament, 6, 6

Stylomandibular tunnel, 38

Sublingual ducts, 14

Sublingual gland

acini, 15

anatomy, 14, 43–44

blood supply, 14

CT scan, 36

embryology, 14

excision, 96–97, 98

complications, 96

for drooling, 323

HIV infection and, 101

imaging, 43–44

innervation, 14

lymphatic drainage, 14, 45

MRI T1 image, 43

mucous escape phenomenon, 49

PET scan, 36

ranula, 95

saliva production, 3

sialolithiasis, 48, 110–111

standardized uptake value (SUV), 35

Sublingual gland tumors

adenocarcinoma, 200

adenoid cystic carcinoma, 56, 56, 210, 211

diagnosis, 202–203

distant metastases, 210–211, 213

hypoglossal nerve, 203, 210

imaging, 203

lingual nerve, 203, 210

malignancy rate, 199–200

mucoepidermoid carcinoma, 211

non-Hodgkin's lymphoma, 273

occurrence, 199

primary lymphomas, 273

prognosis, 210, 211

radiation therapy, 210

synovial cell sarcoma, 270

treatment, 209–211, 211, 212, 213

Sublingual space, 40

Submandibular duct, 13, 40, 43, 73

atresia, 315

dilated, 315

injury to, 96

obstruction, 82, 203

physical characteristics, 110

physical examination, 116

repair, 302, 306

repositioning, 323

and sublingual gland excision, 96–97

transoral sialolithotomy with sialodochoplasty, 116, 118

tumors, 209–210

sialodochoplasty, 210

Submandibular fossa, 13

Submandibular ganglion, 13, 14

Submandibular gland, 6

acini, 15

agenesis, 315

anatomy, 11–14, 40–43

angle of the genu, 110

blood supply, 13

cat scratch disease, 81

CT

density, 23, 41, 43

normal, 36

deep dissection, 13

deep lobe, 12, 13

embryology, 11

excision, 117, 119, 120

facial nerve, 12–13

FDG uptake, 43

HIV infection and, 101

imaging, 40–43

lingual nerve, 13, 14

- lymphangioma, 45
- lymphatic drainage, 13, 45
- mouth, relationship to floor of, 41
- MRI T1 image, 41, 42
- MRI T2 image, 42
- mucous retention cyst, 99
- mylohyoid muscle, relationship to, 41
- parasympathetic innervation, 13–14
- PET scan, 36, 42
- physical examination, 200
- ranula, 95
- saliva
 - composition, **110**
 - production, 3
- sarcoidosis, 143
- sensory innervation, 14
- sialadenitis, 67, 69, 88
 - acute bacterial/viral, 47, 48, 82
 - chronic recurrent, 82–83, 83, 84, 85
- sialolithiasis
 - algorithm, 117
 - predisposition to, 110
 - treatment, 116–122
- sialolithotomy, 116, 118
- sialoliths, 50, 51, 69, 111, 112
 - occurrence, 110–111
- Sjogren's syndrome, 132, 134, 136, 137
- standardized uptake value (SUV), 35
- superficial dissection, 12
- superficial lobe, 11–12, 12
- sympathetic innervation, 14
- traumatic fistulae, 287–288
- ultrasound of, 31
- Submandibular gland tumors
 - adenoid cystic carcinoma, 55, 56, 199, 201
 - diagnosis
 - differential, 200
 - fine needle aspiration biopsy, 202
 - history, 200
 - imaging, 201–202
 - physical examination, 200
 - epithelial-myoeithelial carcinoma, 253
 - extracapsular excision, 203–204, 205, 206
 - grading, 206, 209
 - incidence, 44
 - lipomas, 267
 - lymphangioma, 45
 - lymph node metastases, 278, 280
 - lymphoepithelial carcinoma, 158
 - metastases, 209, 278, 280
 - mucoepidermoid carcinoma, 199
 - occurrence, 199
 - pleomorphic adenoma, 199, 202, 207–208
 - histopathology, 204
 - primary lymphomas, 273
 - prognosis, 206, 209
 - radiation therapy, 206, 209
 - staging, 206, 209
 - vascular tumors, 263, 265
- Submandibular space, 40
 - accessory salivary tissue, 44
 - giant ranula, 49
- Subsigmoid osteotomy, 182
- Superficial musculo-aponeurotic system (SMAS), 4
 - dissection, 176
 - layer to prevent Frey's syndrome, 301, 309
 - mobilization of, 5
- Superficial parotidectomy, 176, 177–179, 182
 - branchial cleft cysts, 321
 - dissected facial nerve, 7
 - metastatic squamous cell carcinoma, 277, 278
- Superficial temporal vessels, 5
- Superparamagnetic iron oxide particles, 31
- Supraomohyoid neck dissection, 208, 209
- Surveillance, Epidemiology and End Results (SEER)
 - database, 199, 206
- Susceptibility artifact, 25–26, 29–30
- Swallowing, difficulty in, 132, 322
- Sympathetic innervation, submandibular gland, 14
- Synovial cell sarcoma, sublingual gland, 270
- Systemic lupus erythematosus, 88
- “Target sign,” 60
- Taste fibers, 17
- Tears
 - break-up time, 132
 - flow, 132
 - lysozyme, 132
- ^{99m}Tc-pertechnetate imaging, 37, 63
 - Warthin's tumor, 55
- Temporomandibular joint, 5
- Temporoparietal flaps, 301
- Tenascin-C, 160
- Terminal duct carcinoma, 238
- ²⁰¹TlCl, 33
- 3-D conformal planning, 307, 309
- Thyroid cancer, 308
- Thyroiditis, mumps, 87
- Time vs. signal intensity curves (TIC), pleomorphic adenomas, 53
- TIMP. *See* Tissue inhibitors of matrix metalloproteinase
- Tissue glues, 296, 309
- Tissue inhibitors of matrix metalloproteinase (TIMP), 131, 160
- Tissues, characteristics on MRI, **26**
- TNM staging, 155; *See also* Staging
- Tobacco smoke, and Warthin's tumor, 171, 189
- Tongue
 - adenoid cystic carcinoma, 236
 - cancer, metastases, 280
 - carcinoma ex-pleomorphic adenoma, 228
 - epithelial-myoeithelial carcinoma, 251

- Tongue (*Continued*)
 impaired movement, 201
 mucoceles, 93
 pleomorphic adenoma, 228
 serous minor salivary glands, 44
- Tonsils, hypertrophy, 49
- Toothbrush trauma, 73
- Total parotidectomy, 176, 179–180, 181, 182
- Transcription factor II-f, 160
- Transit time, CT perfusion, 24
- Transoral partial maxillectomy, mucoepidermoid carcinoma, 237
- Transoral sialolithotomy
 parotid sialoliths, 123, 124
 submandibular sialoliths, 116, 118
- Trastuzumab, 258
- Trismus, 152
- True malignant pleomorphic adenoma, incidence, 229
- Trumpet blower's syndrome, 70, 73
- Tuberculosis, 48, 51; *See also* Mycobacterial disease
- Tubular solid adenoma, 157
- Tumor classification, 150, 151, 167
- Tumors
 molecular profiling, 150, 159–160, 199
 recurrent, choline to creatine ratio, 30
 residual/recurrent, ADC values, 29
- Tympanic neurectomy, 298
- Tympanic plate, 4
- Ultrasonography, 31
 limitations, 63
 lymphangioma, 45
 parotid gland, 40
 parotid tumors, 172–173, 174
 technique, 32
 vascular lesions, 46
- Undifferentiated carcinomas, 157
- Undifferentiated carcinoma with lymphoid stroma, 158
- Upper lip. *See* Lip, upper
- U.S. Public Health Service (USPHS), 150
- Utrecht line, 172–173
- Uveitis, 143, 147
- Uveoparotid fever, 143, 147
- Validation, independent, 150
- Vascularity, Doppler ultrasonography, 32
- Vascular lesions
 hemangioma, 46–47
 lymphangioma, 45–46
 MRA, 46
 physical examination, 200
 ultrasound of, 46
- Vascular pulsation artifact, 29–30
- Vein grafts, 302
- Venous anomalies, and lymphangiomas, 46
- Viral (V) antibodies, 87
- von Hippel Lindau gene, 160
- Von Recklinghausen's disease, 58
- Warthin's tumor, 151, 189
 ADC values, 29
 choline to creatine ratio, 30
 diagnostic imaging, 54–55, 54
 enhancement curve, 30
 etiology, 171
 histopathology, 173
 parotid tail, 172
^{99m}Tc-pertechnetate uptake, 55
 time to peak, 24
- Water, secretion of, 17
- Weber-Ferguson incision, 136
- Wegener's granulomatosis, 140, 141
- Wharton's duct, 13, 40, 43, 73
 atresia, 315
 dilated, 315
 injury to, 96
 obstruction, 82, 201
 physical characteristics, 110
 physical examination, 116
 repair, 302, 306
 repositioning, 323
 and sublingual gland excision, 96–97
 transoral sialolithotomy with sialodochoplasty, 116, 118
 tumors, 207–208
 sialodochoplasty, 208
- Wide field adjuvant radiation therapy, 195
- Window widths (WW), 22
- Wnt/ β -catenin signaling pathway, 159
- Xerophthalmia, 323
- Xerostomia, 129
 aplasia, 315
 preventative drugs, 307–308
 radiation injury, 306–307
 Sjogren's syndrome and, 130
 surgical approach to prevention, 308
- X-ray diffraction analysis (EDX), sialoliths, 109
- X-rays, fan beam, 20